Study Evaluating SHEN26 Capsule in Patients With Mild to Moderate COVID-19
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-parallel-controlled phase III
clinical trial. It is designed to evaluate the efficacy and safety of SHEN26 capsules in
Chinese adult patients with mild to moderate COVID-19